Alnuctamab for Refractory SLE (LATTE Study)

Summary

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

Timeline

Start

2026-03-17

Primary completion

2027-12-01

Completion

2027-12-01

Drugs

Indications